VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 23, 2007) - Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) reported today that its development partner Hana Biosciences, Inc. (NASDAQ: HNAB) presented promising interim Phase 1 clinical data for cancer product candidate Alocrest™ (vinorelbine tartrate injection, OPTISOME™) at the "Molecular Targets and Cancer Therapeutics" International Conference in San Francisco, CA.
